Addyi vs Vyleesi vs testosterone for women: approved products and off-label hormone use are different
Addyi and Vyleesi are FDA-approved products for different labeled populations with acquired, generalized HSDD, routes, and schedules. No testosterone product is FDA approved in the United States for female sexual dysfunction, so off-label and compounded testosterone follow different product and evidence pathways.
Addyi (flibanserin) and Vyleesi (bremelanotide) are different FDA-approved medicines for acquired, generalized hypoactive sexual desire disorder, but their current labeled populations are not the same: Addyi is indicated for women younger than 65, while Vyleesi is indicated for premenopausal women. Addyi is scheduled oral treatment; Vyleesi is a subcutaneous product used before anticipated sexual activity under its label. No testosterone product is FDA approved in the United States specifically for female sexual dysfunction.1234
This is not a ladder from weak to strong. The diagnosis, population, route, timing, contraindications, interactions, adverse effects, evidence and follow-up differ. A low laboratory testosterone result does not by itself establish HSDD or select among them.
Compare the regulatory product before comparing promises
| Path | Regulatory and use identity | Record to verify |
|---|---|---|
| Addyi | FDA-approved flibanserin oral product for women younger than 65 who meet its product-specific HSDD indication | Current prescribing information, scheduled dosing, interactions, warnings and discontinuation criteria |
| Vyleesi | FDA-approved bremelanotide autoinjector for premenopausal women who meet its product-specific HSDD indication | Current prescribing information, timing, maximum-use limits, contraindications and adverse effects |
| Approved testosterone used off label | An FDA-approved testosterone product prescribed outside its labeled population or purpose | Exact finished product, approved label, proposed formulation/exposure, rationale and monitoring |
| Compounded testosterone | A compounded preparation that is not an FDA-approved finished drug | Pharmacy, formula, concentration, route, compounding basis, quality record and prescription |
Approval of Addyi does not approve every flibanserin schedule. Approval of Vyleesi does not transfer to another peptide or an unapproved compounded injection. Approval of a testosterone gel for a labeled male population does not become an approved female product when a clinic uses a smaller amount.
The diagnosis gate is part of the label
The approved HSDD products use a defined condition rather than a generic promise to increase libido. The label context excludes desire change better explained by another medical or psychiatric condition, relationship problems, or a medicine or drug effect. The history therefore matters more than a single hormone panel or marketing quiz.
Record when the concern began, whether it is generalized or situation-specific, distress, menopause status, pain or genitourinary symptoms, sleep, mood, medicines, substances, relationship context and relevant health conditions. That assessment is not a moral judgment; it keeps unlike problems from being sold the same protocol.
The September 2026 FDA public meeting on testosterone use in menopausal women reflects current attention and evidence gaps.1 A public meeting, expert presentation or docket comment is not approval, a new indication or a substitute for a finished-product label.
Route and schedule create different exposures
Addyi’s scheduled oral use creates a continuing medicine, interaction and adherence record. Vyleesi’s injectable presentation creates storage, device, timing, maximum-frequency and injection-use questions. Testosterone exposure depends on the exact formulation and route: gel, cream, patch, implant, injection or another presentation cannot be treated as interchangeable milligrams.
Compare the complete burden rather than the marketing convenience. Include acquisition, pharmacy, training, scheduled or as-needed use, monitoring, adverse-effect contact, follow-up and the plan when the intended outcome does not improve within the label’s stated decision window.
Testosterone level is not a universal desire score
Professional guidance discusses a bounded role for systemic testosterone in selected women, but it does not create an FDA-approved product or validate a clinic’s proprietary target range.5 Assay method, units, timing, binding proteins, formulation, exposure and clinical context affect interpretation. A number should not be converted into proof that testosterone caused the concern or that more is better.
If testosterone is proposed, ask why this exact product and route were chosen, whether the use is off label or compounded, what exposure range and adverse effects are being monitored, and what finding stops or changes treatment. The testosterone-for-women guide provides the deeper product-status audit.
Build a source-to-claim record
Do not compare response percentages from unlike trials as though they were head-to-head. Check population, baseline definition, outcome, duration, missing-data handling and funding. The most useful endpoint is not a testimonial; it is a predeclared measure, assessment date and stop-or-reassess rule.
A consultation framework
- 1. Define the concern Separate acquired generalized low desire with distress from pain, arousal, orgasm, relationship, medicine, mood, sleep and genitourinary concerns.
- 2. Name the product path Record Addyi, Vyleesi, an approved testosterone product used off label, or a compounded preparation without blending their status.
- 3. Read the current label Match population, route, schedule, contraindications, interactions, warnings and decision window.
- 4. Audit the evidence transfer Confirm that the cited study used the same population, product, route, exposure and outcome.
- 5. Write monitoring and access Identify follow-up, adverse-effect contact, laboratory role when relevant, pharmacy, total program cost and record transfer.
- 6. Define the exit State what lack of benefit, adverse effect, life change or access problem triggers stopping or a new assessment.
The decisive question is not which product is strongest. It is whether the diagnosis, finished product, regulatory path, evidence, exposure and follow-up form one coherent record.
Sources
- U.S. Food and Drug Administration. FDA Public Meeting: Testosterone Use in Menopausal Women. Current federal discussion of growing off-label use, product gaps and evidence questions. Accessed .
- U.S. Food and Drug Administration. Addyi prescribing information. Current flibanserin indication for women younger than 65, schedule, limitations, warnings, and discontinuation criteria. Accessed .
- U.S. Food and Drug Administration. Drugs@FDA: Vyleesi. Approval history and current product documents for bremelanotide. Accessed .
- U.S. Food and Drug Administration. Testosterone information. Current FDA status and safety context for approved testosterone products. Accessed .
- International Society for the Study of Women's Sexual Health. Clinical practice guideline for systemic testosterone for HSDD in women. Professional evidence and monitoring framework, used without converting a guideline into FDA approval. Accessed .